ZetaGen Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Series B1
- Latest Deal Amount
-
$12.9M
- Investors
-
6
ZetaGen Therapeutics General Information
Description
Developer of a small molecule-based osteoinductive technology designed to suspend cancer, inhibit pain and regenerate bone. The company's technology can transform the treatment of bone-related injuries, procedures and diseases, suspend cancer growth, alleviate pain and promote bone regeneration, enabling healthcare professionals to encompass several oncological candidates targeting metastatic and primary cancers for breast, lung, prostate and bone sarcomas.
Contact Information
Website
www.zetagen.comCorporate Office
- 841 East Fayette Street
- Suite 1100
- Syracuse, NY 13210
- United States
Corporate Office
- 841 East Fayette Street
- Suite 1100
- Syracuse, NY 13210
- United States
ZetaGen Therapeutics Timeline
ZetaGen Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series B1) | 12-Nov-2025 | $12.9M | Completed | Clinical Trials - General | ||
| 6. Later Stage VC | 23-Jan-2025 | Completed | Clinical Trials - General | |||
| 5. Later Stage VC (Series B) | 06-Feb-2023 | Completed | Clinical Trials - General | |||
| 4. Grant | 30-Nov-2021 | Completed | Clinical Trials - General | |||
| 3. Later Stage VC (Series A) | 06-Feb-2020 | Completed | Clinical Trials - General | |||
| 2. Grant | 11-Sep-2019 | $225K | Completed | Clinical Trials - General | ||
| 1. Grant | 05-Sep-2018 | $1.01M | Completed | Clinical Trials - General |
ZetaGen Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B1 | ||||||||
| Series B | ||||||||
| Series A | 7,226,782 | $0.000100 | 3% | $1.9 | $1.9 | 1x | $1.9 | 23.97% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
ZetaGen Therapeutics Comparisons
Industry
Financing
Details
ZetaGen Therapeutics Competitors (2)
One of ZetaGen Therapeutics’s 2 competitors is Cerapedics, a Venture Capital-Backed company based in Westminster, CO.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cerapedics | Venture Capital-Backed | Westminster, CO | ||||
| Medtronic | Corporation | Minneapolis, MN |
ZetaGen Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ZetaGen Therapeutics Patents
ZetaGen Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12403118-B1 | Cancer treatments using modified fatty acids and the carriers to administer them | Active | 05-Mar-2025 | ||
| US-20260263411-A1 | Cancer treatments using modified fatty acids and the carriers to administer them | Pending | 05-Mar-2025 | ||
| WO-2026187860-A1 | Cancer treatments using modified fatty acids and the carriers to administer them | Pending | 05-Mar-2025 | ||
| US-20260151427-A1 | Lanthanum compositions for treating cancer | Pending | 02-Dec-2024 | ||
| WO-2026122408-A1 | Lanthanum compositions for treating cancer | Pending | 02-Dec-2024 | A61K31/485 |
ZetaGen Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ZetaGen Therapeutics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AJU IB Investment | Venture Capital | Minority | ||
| Upstate Biotech Ventures | Venture Capital | Minority | ||
| JSTAR Capital | Venture Capital | Minority | ||
| New York Ventures | Corporate Venture Capital | Minority | ||
| National Institutes of Arthritis and Musculoskeletal Diseases | Not-For-Profit Venture Capital |
ZetaGen Therapeutics FAQs
-
When was ZetaGen Therapeutics founded?
ZetaGen Therapeutics was founded in 2015.
-
Where is ZetaGen Therapeutics headquartered?
ZetaGen Therapeutics is headquartered in Syracuse, NY.
-
What is the size of ZetaGen Therapeutics?
ZetaGen Therapeutics has 9 total employees.
-
What industry is ZetaGen Therapeutics in?
ZetaGen Therapeutics’s primary industry is Drug Discovery.
-
Is ZetaGen Therapeutics a private or public company?
ZetaGen Therapeutics is a Private company.
-
What is ZetaGen Therapeutics’s current revenue?
The current revenue for ZetaGen Therapeutics is .
-
How much funding has ZetaGen Therapeutics raised over time?
ZetaGen Therapeutics has raised $52.5M.
-
Who are ZetaGen Therapeutics’s investors?
AJU IB Investment, Upstate Biotech Ventures, JSTAR Capital, New York Ventures, and National Institutes of Arthritis and Musculoskeletal Diseases are 5 of 6 investors who have invested in ZetaGen Therapeutics.
-
Who are ZetaGen Therapeutics’s competitors?
Cerapedics and Medtronic are competitors of ZetaGen Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
